| scholarly article | Q13442814 |
| P50 | author | Aurora S Blucher | Q89111566 |
| P2093 | author name string | Guanming Wu | |
| Shannon K McWeeney | |||
| Molly Kulesz-Martin | |||
| Gabrielle Choonoo | |||
| P2860 | cites work | Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. | Q40657525 |
| DGIdb: mining the druggable genome | Q41917589 | ||
| ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. | Q44106085 | ||
| Analysis of Commercial and Public Bioactivity Databases | Q44456428 | ||
| The druggable genome and support for target identification and validation in drug development. | Q48347170 | ||
| Data completeness—the Achilles heel of drug-target networks | Q57012660 | ||
| Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine | Q63199223 | ||
| Genomic sciences and the medicine of tomorrow | Q74677443 | ||
| DrugBank: a comprehensive resource for in silico drug discovery and exploration | Q24188653 | ||
| TTD: Therapeutic Target Database | Q24548461 | ||
| DrugBank 4.0: shedding new light on drug metabolism | Q24568341 | ||
| International network of cancer genome projects | Q24611474 | ||
| KEGG for representation and analysis of molecular networks involving diseases and drugs | Q24644514 | ||
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| Notch signaling: an emerging therapeutic target for cancer treatment | Q26784068 | ||
| Emerging patterns of somatic mutations in cancer | Q27014126 | ||
| STITCH 4: integration of protein-chemical interactions with user data | Q27136674 | ||
| The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands | Q27136827 | ||
| The ChEMBL bioactivity database: an update | Q27144224 | ||
| DrugCentral: online drug compendium | Q27697588 | ||
| Quantitative assessment of the expanding complementarity between public and commercial databases of bioactive compounds | Q27701890 | ||
| A multi-label approach to target prediction taking ligand promiscuity into account | Q27902280 | ||
| Target prediction utilising negative bioactivity data covering large chemical space | Q27902317 | ||
| PubChem as a public resource for drug discovery | Q28111749 | ||
| Structure and chemical inhibition of the RET tyrosine kinase domain | Q28259608 | ||
| A quantitative analysis of kinase inhibitor selectivity | Q28264038 | ||
| How many drug targets are there? | Q28276660 | ||
| Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells | Q28277030 | ||
| Network pharmacology: the next paradigm in drug discovery | Q28297997 | ||
| Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors | Q28475474 | ||
| Large-Scale Off-Target Identification Using Fast and Accurate Dual Regularized One-Class Collaborative Filtering and Its Application to Drug Repurposing | Q28554586 | ||
| BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology | Q28603124 | ||
| The Drug Repurposing Hub: a next-generation drug library and information resource | Q29363901 | ||
| The druggable genome | Q29547361 | ||
| Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 | ||
| Global mapping of pharmacological space | Q29615876 | ||
| Comprehensive analysis of kinase inhibitor selectivity | Q29616719 | ||
| Compound promiscuity: what can we learn from current data? | Q30605924 | ||
| In silico target predictions: defining a benchmarking data set and comparison of performance of the multiclass Naïve Bayes and Parzen-Rosenblatt window | Q30653633 | ||
| Predicting drug side-effect profiles: a chemical fragment-based approach | Q33903536 | ||
| Collation and data-mining of literature bioactivity data for drug discovery | Q34026765 | ||
| Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer | Q34084254 | ||
| PubChem's BioAssay Database | Q34090643 | ||
| Role of systems pharmacology in understanding drug adverse events | Q34134791 | ||
| Trends in the exploitation of novel drug targets | Q34205159 | ||
| The BATTLE trial: personalizing therapy for lung cancer | Q34275011 | ||
| Notch inhibitors for cancer treatment | Q34330869 | ||
| Drugs, their targets and the nature and number of drug targets | Q34571023 | ||
| PubChem BioAssay: 2014 update | Q35033308 | ||
| Exploiting drug-disease relationships for computational drug repositioning | Q35109885 | ||
| Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial | Q35168763 | ||
| The Reactome pathway Knowledgebase | Q35866115 | ||
| Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). | Q35904572 | ||
| Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information | Q36434850 | ||
| Multitargeted therapy: can promiscuity be praised in an era of political correctness? | Q36537296 | ||
| Open Targets: a platform for therapeutic target identification and validation | Q37556749 | ||
| Pharos: Collating protein information to shed light on the druggable genome | Q37556791 | ||
| KEGG: new perspectives on genomes, pathways, diseases and drugs | Q37556832 | ||
| Comparing the Chemical Structure and Protein Content of ChEMBL, DrugBank, Human Metabolome Database and the Therapeutic Target Database | Q37564801 | ||
| Systems pharmacology of adverse event mitigation by drug combinations | Q37658567 | ||
| On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors | Q37987207 | ||
| The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication | Q38135497 | ||
| Prioritizing targets for precision cancer medicine | Q38262620 | ||
| NCI Thesaurus: a semantic model integrating cancer-related clinical and molecular information | Q38406992 | ||
| FDA-approved small-molecule kinase inhibitors. | Q38480289 | ||
| SuperTarget goes quantitative: update on drug-target interactions | Q38499993 | ||
| Patient-centric trials for therapeutic development in precision oncology. | Q38607709 | ||
| Precision oncology: origins, optimism, and potential | Q38730155 | ||
| A comprehensive map of molecular drug targets. | Q39026969 | ||
| Precision medicine needs randomized clinical trials | Q39124225 | ||
| Evidence-Based and Quantitative Prioritization of Tool Compounds in Phenotypic Drug Discovery | Q39592577 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 1085-1099 | |
| P577 | publication date | 2017-09-27 | |
| P1433 | published in | Trends in Pharmacological Sciences | Q2451474 |
| P1476 | title | Evidence-Based Precision Oncology with the Cancer Targetome | |
| P478 | volume | 38 |
| Q59793939 | Advances in multiple omics of natural-killer/T cell lymphoma |
| Q58598813 | Functional genomic landscape of acute myeloid leukaemia |
| Q59086861 | Functional genomic landscape of acute myeloid leukaemia |
| Q90611166 | Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma |
| Q54977396 | Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models. |
| Q52725991 | Montagna Symposium 2017-Precision Dermatology: Next Generation Prevention, Diagnosis, and Treatment. |
| Q92862439 | Natural Product Target Network Reveals Potential for Cancer Combination Therapies |
| Q64259068 | Precision medicine review: rare driver mutations and their biophysical classification |
| Q62648881 | Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers |
| Q92355875 | Visualization of drug target interactions in the contexts of pathways and networks with ReactomeFIViz |
Search more.